BRIEF-Halozyme Therapeutics sees FY 2017 revenue $115 mln to $130 mln
January 09, 2017 at 18:10 PM EST
* Halozyme Therapeutics-expects to report $20 million in 2016 revenue for reimbursed partner research and development expenses
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.